"I am pleased with the performance during the third quarter of 2020. First and foremost, we experienced a continued increase in the clinical usage of the Episealer® technology, best evidenced by a record 88 Episealer® orders approved. This figure represents an increase of 57% compared to the same period in 2019, and a 76% increase compared to Q2 2020. We have increased the number of users during the year, and surgeries have taken place 12 countries during 2020. We are creating a strong foundation for the future, and I believe this growth is impressive during the experimental and clinical phase, and we must not forget the current pandemic and its impact on elective surgeries", says Pål Ryfors, CEO
Third quarter 2020 compared to 2019, Group
· Gross order intake amounted to
· Order backlog amounted to
· Group net sales increased by 33% to
· Loss for the period amounted to
· Earnings per share amounted to
First nine months 2020 compared to first nine months 2019, Group
· Gross order intake amounted to
· 48% increase in orders for Episealer® implants during the first nine months with 206 (139) approved orders
· Group net sales decreased by 3% to
· Loss for the period amounted to
· Earnings per share amounted to
Significant events during the third quarter
· Results from Swedish multi-centre clinical trial with follow-up of 30 Episealer® patients was accepted for scientific publication
· Results from European multicenter study with follow-up of 80 Episealer® patients was accepted for scientific publication
·
·
·
· Episealer® implants were approved for sale in
· Episealer® surgery in
· First surgery was performed in
·
Significant events after the third quarter
· The first Episealer® surgery was performed in the US
·
For more information, please contact:
Pål Ryfors, CEO,
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com)
About
This information is information that
https://news.cision.com/episurf/r/interim-report-1-july---30-september-2020,c3221392
https://mb.cision.com/Main/14691/3221392/1323016.pdf
https://news.cision.com/episurf/i/img-0176,c2841762
(c) 2020 Cision. All rights reserved., source